4D Molecular Therapeutics (FDMT) Operating Income Growth (1y) (2021 - 2026)
4D Molecular Therapeutics (FDMT) Operating Income Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 2,150.96% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 706.51 Mn | 315.62 Mn | - | -37.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.30% |
| Dec 31, 2025 | 126.22% |
| Sep 30, 2025 | -19.66% |
| Jun 30, 2025 | -40.04% |
| Mar 31, 2025 | -40.60% |
| Dec 31, 2024 | -53.11% |
| Sep 30, 2024 | -265.91% |
| Jun 30, 2024 | -32.11% |
| Mar 31, 2024 | -26.67% |
| Dec 31, 2023 | -27.62% |
| Sep 30, 2023 | 47.26% |
| Jun 30, 2023 | -13.05% |
| Mar 31, 2023 | -14.07% |
| Dec 31, 2022 | -15.97% |
| Sep 30, 2022 | -16.92% |
| Jun 30, 2022 | -274.22% |
| Mar 31, 2022 | -61.79% |
| Dec 31, 2021 | -21.26% |
| Sep 30, 2021 | -189.93% |
| Jun 30, 2021 | 49.86% |